SCHEMBL16398486

SCHEMBL16398486

O=C(O)c1cc(C(F)F)ccc1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 4/20 0.43
TDP1 Q9NUW8 3/20 0.43
MEN1 O00255 2/20 0.43
CYP2C9 P11712 2/20 0.43
CYP2C19 P33261 2/20 0.43
KMT2A Q03164 2/20 0.43
CYP2D6 P10635 1/20 0.43
GRM8 O00222 1/20 0.43
GRM6 O15303 1/20 0.43
SLC6A2 P23975 1/20 0.43
SLC6A4 P31645 1/20 0.43
DRD3 P35462 1/20 0.43
GRM4 Q14833 1/20 0.43
MRGPRX4 Q96LA9 2/20 0.41
CES2 O00748 1/20 0.41
CES1 P23141 1/20 0.41
KDM4E B2RXH2 4/20 0.41
ALDH1A1 P00352 3/20 0.41
HPGD P15428 3/20 0.41
GRM1 Q13255 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31280455 1.00 HSD17B10 (0.43) HSD17B10TDP1MEN1CYP2C9CYP2C19
SCHEMBL12089542 0.86 EIF4A3 (0.47) HSD17B10TDP1MEN1CYP2C9CYP2C19
SCHEMBL13633350 0.85 MEN1 (0.41) HSD17B10TDP1MEN1CYP2C9CYP2C19
SCHEMBL3925212 0.85 MEN1 (0.41) HSD17B10TDP1MEN1CYP2C9CYP2C19
SCHEMBL1498847 0.84 MRGPRX4 (0.48) HSD17B10TDP1MEN1CYP2C9CYP2C19
SCHEMBL19613652 0.82 CES2 (0.39) MEN1CYP2C9CYP2C19KMT2ADRD3
SCHEMBL21064545 0.80 LMNA (0.45) HSD17B10KMT2AKDM4EALDH1A1HPGD
SCHEMBL27531056 0.78 KEAP1 (0.58) HSD17B10TDP1MEN1CYP2C9CYP2C19
SCHEMBL16398002 0.78 ALDH1A1 (0.43) HSD17B10KMT2ASLC6A4KDM4EALDH1A1
SCHEMBL15934468 0.76 ALDH1A1 (0.62) HSD17B10TDP1MEN1CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4727924-A1 INHIBITORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION ONO Pharmaceutical Co., Ltd. (JP) 2026-04-22 EP disclosed
WO-2024255743-A1 INHIBITORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION ONO PHARMACEUTICAL CO., LTD. (JP) 2024-12-19 WO disclosed
US-11203571-B2 Sulfonamides as modulators of sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2021-12-21 US disclosed
US-11203571-B2 Sulfonamides as modulators of sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2021-12-21 US disclosed
EP-3022175-B1 SULFONAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMA (US) 2017-11-08 EP disclosed
EP-3022175-B1 SULFONAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMA (US) 2017-11-08 EP disclosed
US-20160152561-A1 SULFONAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS (SAN DIEGO) LLC 2016-06-02 US disclosed
US-20160152561-A1 SULFONAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS (SAN DIEGO) LLC 2016-06-02 US disclosed
EP-3022175-A1 SULFONAMIDES AS MODULATORS OF SODIUM CHANNELS Vertex Pharmaceuticals Inc. (US) 2016-05-25 EP disclosed
WO-2015010065-A1 SULFONAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-01-22 WO disclosed
WO-2015010065-A1 SULFONAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11203571-B2 Sulfonamides as modulators of sodium channels TRPV1, SCN1A, SCN5A HSD17B10 2715/4885TDP1 3754/4885MEN1 3744/4885
US-20160152561-A1 SULFONAMIDES AS MODULATORS OF SODIUM CHANNELS TRPV1, SCN1A, SCN5A HSD17B10 2715/4885TDP1 3754/4885MEN1 3744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.